semaj83/ctmatch_classification huggingface dataset:
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Seasonal Affective Disorder Patient has a history of Major Depressive Disorder (MDD) with a seasonal pattern  Patient has a current or past history of seizure disorder or brain injury Patient has a history or current diagnosis of anorexia nervosa or bulimia Patient has recurrent summer depression more frequently than winter depression Patient has primary diagnosis of panic disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD), acute distress disorder, bipolar II disorder or other psychotic disorders Patient has initiated psychotherapy within the last 3 months
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 10.0-55.0,  Involutional Depression Anxiety Disorders Age: 10-30 Can give consent/assent. Parents will provide consent for all minors All subjects will have IQ greater than 80 High risk Psychopathology: Offspring of adults with a history of MDD Low risk Psychopathology: Offspring of adults with no history of MDD and low developmental levels of emotion dysregulation. Subjects born to parents with only anxiety disorders will be included in this group  Any medical condition that increases risk for MRI (e.g. pacemaker, metallic foreign body in eye) Pregnancy Both groups: All subjects will be free of current impairing affective disorders, separation anxiety disorder, social anxiety disorder, panic disorder, generalized anxiety disorder, PTSD, ADHD, as well as lifetime history of substance dependence, psychosis, pervasive developmental disorder, major affective disorder, obsessive compulsive disorder, conduct disorder, anorexia. All subjects will be born to parents with no history of schizophrenia or bipolar disorder Age: 18-55 Can give consent/assent Offspring: All subjects will have offspring participating in this same protocol Have an IQ greater than 80 Past history of MDD No lifetime history of MDD ADULT
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Depression Palliative Care Cancer Mental Disorder Either enrolled in the OHSU radiology/oncology clinic or VA palliative care, and living within 120 miles of the Portland VAMC Life-limiting disease is any type of solid or blood cancer Eighteen years of age or older Life expectancy of 1 year or less as reflected by hospice admission or palliative care status. Although exact life expectancy can not be predicted, actively dying patients with estimated life expectancy of < 10 days are unlikely to be enrolled Diagnosis of major depression disorder as determined by the Structured Clinical Interview for Diagnosis (SCID) Significant depressive cognitive symptomatology as determined by a MADRS greater than 19 Currently taking an SSRI but still depressed enough to meet or not taking SSRI but depressed enough to start on SSRI Willing and able to give informed consent to participate in this study as demonstrated by the MacArthur Competence Assessment Tool for clinical research Speaks/understands English For patients at home who cannot self-administer medications, has a caregiver who can assist with administering medication  Dementia or Delirium as determined by the Short Portable Mental Status Questionnaire (SPMSQ) score of less than 7 Diagnosis of delirium as determined by the Confusional Assessment Method (CAM) Any of the following Brief Psychiatric Rating Scale (BPRS) items rated 4 -, elated mood, suspiciousness, hallucinations, excitement, distractibility or motor hyperactivity Severe insomnia Severe anxiety Significant suicidal ideation History of current mental disorder in which depressive symptoms occur, but for which psychostimulants are contraindicated (schizophrenia and bipolar disorder will be based on history; active psychotic symptoms on selected BPRS items) History of stimulant abuse or other active, severe substance abuse Contraindications to methylphenidate or an SSRI including significant cardiac arrhythmias; uncontrolled, severe hypertension; moderate-severe angina; seizure disorder; severe COPD; use of medications such as Levodopa, monoamine oxidase inhibitors, and lithium; diagnosis of narrow-angle glaucoma; or history of SSRI-induced hyponatremia Physical symptoms including increased blood pressure (DBP greater than 115, SBP greater than 180), pulse greater than 120, irregular pulse, or chest pain consistent with angina
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 14.0-75.0,  Depression (1) age 14-18 years and (2) one risk factor for developing depression in the next two years: sub-clinical depressed mood (not meeting of major depression) a family history of depression in a parent or sibling, or past personal history of depression or personal perception of risk depression and desire to participate  meeting or undergoing active treatment for major depression (5 or more symptoms nearly every day with functional impairment, minor depression) bipolar disorder panic disorder conduct disorder substance abuse or having suicidal ideation Active treatment for depression is defined as receiving anti-depressant medication or counseling within one year of remission of symptoms from the most recent episode Those who meet DSM-IV for minor depression (3-4 symptoms) or who report significant functional impairment (very difficult or above on the Prime MD functional impairment scale) will be notified and offered a referral for an evaluation by a mental health specialist (and will be strongly encouraged to attend) Those with 1-2 symptoms of depression will also be offered evaluation and treatment from a mental health specialist. In each case, the primary care physician will be notified and the parents (if under the age of 19)
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 14.0-25.0,  Depressive Disorder, Major Cannabis Abuse DSM-IV diagnosis of current marijuana abuse or dependence, confirmed by SCID-SUD DSM-IV diagnosis of current major depressive disorder, confirmed by the K-SADS Marijuana use of at least two days within the week prior to enrollment Demonstrated adequate levels of depressive symptoms within the week prior to enrollment  DSM-IV diagnosis of bipolar disorder, schizoaffective disorder, or schizophrenia Hypo or hyperthyroidism Significant cardiac, neurological, or kidney impairment Liver disease (SGOT, SGPT, or gamma-GTP greater than 3 times the normal level) Use of antipsychotic or antidepressant medication in the month prior to enrollment DSM-IV dependence on any substance except marijuana or nicotine; alcohol dependence, or history of drug use History of significant medication side effects from any SSRI antidepressant Pregnant Unable to use adequate contraceptive methods for the duration of the study Inability to read or understand English
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Major Depressive Disorder. Hepatitis C, Chronic Patients with chronic hepatitis C who are going to initiate treatment with peginterferon alfa2a + ribavirin Age 18-65 years Signed informed consent If female, they are not in fertile period or they use barrier contraceptives Patients able to understand and fill written questionnaires  Hepatic cirrhosis or carcinoma Less than 4000/mm3 leucocytes, or less than 70000/mm3 platelets Hemoglobin less than 11 g/dL (females) or 12 (males) Any risk factor for hemolysis Comorbid severe medical conditions (kidney, immune system, lung, heart, thyroid, etc) Baseline mental disorders that require antidepressants (depressive disorders and anxiety disorders) Other baseline mental disorders (delirium, substance use disorders) Mental disorders at any time (dementia, psychotic disorders, bipolar disorders Contraindications of escitalopram (hypersensibility, diabetes, patients using serotoninergic agents, drugs that enhance the risk of bleeding, or monoamineoxidase inhibitors -MAOIs-)
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Unipolar Depression Male or female 18 years or older DSM-IV diagnosis of major depressive disorder of at least moderate severity, but without psychotic features Ham-D 17 score of 18 or above Have a documentable history of 2 prior adequate trials of antidepressants including an SSRI without sufficient response. A clinically adequate trial is defined as having taken a minimum effective dose of an antidepressant for at least 3 weeks without a significant change in depressive symptoms Must be currently on an serotonin uptake inhibitor (to venlafaxine or duloxetine) at an adequate dose for at least 3 weeks Ability and willingness to provide consent for participation in the study  Any medical condition that would preclude treatment with an SSRI, risperidone, or bupropion ER Any clinically significant unstable medical condition Diagnosis of bipolar disorder or a primary diagnosis of any psychotic disorder Current psychotic symptoms (hallucination or delusions) Alcohol or drug abuse or dependence in the last 3 months (excluding nicotine and caffeine dependence/abuse) or abuse within the last month Documented non-response to the combination of a novel antipsychotic or bupropion ER and a SSRI Concomitant use of any psychotropic other than an SSRI or zolpidem (PRN for sleep) Score of 4 on the suicide item of the Ham-D scale and determination by the investigator of significant suicide risk Known sensitivity to risperidone or bupropion ER
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Major Depressive Disorder (All three groups) age 18-55 years satisfactory physical health education level and a degree of understanding to communicate effectively with the investigator c capable of providing informed consent female subjects of childbearing potential, a medically accepted means of contraception Additional for the patient groups DSM-IV-TR for a diagnosis of BD or MDD currently meeting for an MDE and a Hamilton Depression Rating Scale 17 Item (HDRS-17) score of > 17  (All three groups) DSM-IV-TR for substance abuse or dependence (except nicotine or caffeine) within the past 6 months comorbid neurological or other major psychiatric disorders as defined in the DSM-IV-TR history of neurological trauma resulting in loss of consciousness uncorrected hypothyroidism or hyperthyroidism, including elevated thyroid stimulating hormone (TSH) other unstable medical condition female subjects who are pregnant or nursing Additional for the BD and MDD group prior failure to respond to fluoxetine and olanzapine in combination at adequate dose and duration
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Atypical Depression adults 18-65 years of age DSM-IV for major depressive episode with atypical features as assessed by the Atypical Depression Diagnostic Scale minimum score of 18 on the Hamilton Depression Scale (29-item version) at baseline baseline Clinical Global Impressions Severity score of 4 or more written informed consent negative serum pregnancy test for women of childbearing potential  any current primary DSM-IV Axis I disorder other than depression history of DSM-IV diagnosis of bipolar I disorder, schizophrenia or other psychotic disorder, mental retardation or other pervasive developmental disorder, or cognitive disorder due to a general medical condition history of substance abuse or dependence within the last 3 months suicide risk or serious suicide attempt with the last year clinically significant medical condition or laboratory or EKG abnormality history of non-response to three prior adequate trials of antidepressants women of childbearing potential who are unwilling to practice an acceptable method of contraception history of hypersensitivity to modafinil use of an investigational medication within the last 28 days use of antidepressant medication with 28 days of screening
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Diabetes Mellitus, Type 2 Diagnosis of type 2 diabetes HbA1C <= 12.0% within the past 12 months BMI <= 45.0 kg/m2 Initiation, addition of, change to, or continuation of basal insulin therapy with insulin detemir as deemed necessary by Investigator  Anticipated change in concomitant medication known to interfere with glucose metabolism such as systemic steroids, non-selective beta-blockers or mono amine oxidase (MAO) inhibitors Proliferative retinopathy or maculopathy that has required acute treatment within the last 6 months Any glucose lowering medication that is not indicated in combination with insulin, such as GLP-1 Analogues Known hypoglycemia unawareness or recurrent major hypoglycemia, as judged by the Investigator
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Major Depressive Disorder Male or female patients 18-65 years of age, inclusive
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Atypical Depression DSM-IV Major Depression or Dysthymia with Atypical Features Age 18-65 Physically healthy HAMD(24) > 14  Prior experience with Duloxetine History of Psychosis or Bipolar Disorder, Borderline Personality Disorder Unstable medical disorder; any history of Epilepsy Currently taking medication that can interact with Duloxetine Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol) Serious suicidal ideation judged at least somewhat likely to be acted upon or require hospitalization Current (past two weeks) use of psychoactive medication (four weeks for Fluoxetine) Pregnancy Currently breast feeding Fecund women failing to use acceptable birth control
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Depression Anxiety Student with above average levels of depression and anxiety symptoms (students with average or below average symptoms will be enrolled into the study space permitting)  Not a student in a participating school Not a student in grades six through eight
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Advanced Cancers Have weight loss of > 5% within the last 6 months Present with anorexia, fatigue and one of the following: anxiety, depression or sleep disturbances, during the preceding 24 hours, with an average intensity of each symptom >/= 3 on a scale of 0 to 10, in which 0=no symptom, and 10= the worst possible symptom Describe the symptoms as being present every day for a minimum of 2 weeks Have no clinical evidence of cognitive failure Must be 18 years or older Expect to live at least >/= 4 weeks Must have negative serum pregnancy test within 24 hours of study enrollment in women of childbearing potential. FDA for the status of not of childbearing potential, hysterectomy, or menopausal for 24 consecutive months Understand and sign written informed consent Have no concurrent steroids with the exception of steroids used concurrently with chemotherapy as part of a regimen or to reduce nausea Willing and able to comply with S.T.E.P.S.[System for Thalidomide Education and Prescribing Safety]  Have major contraindication to thalidomide, i.e. hypersensitivity Present with National Cancer Institute (NCI) Common Toxicity Grade 3 or more peripheral neuropathy Are not able to complete the baseline assessment forms Are pregnant or lactating Patients with clinical history of seizures Patients with an ANC of </= 750 at time of study enrollment will be excluded (to be drawn within 14 days prior to registration) Patients with a history of Acquired Immune Deficiency Syndrome (AIDS), systemic lupus erythematous, or renal failure as defined by a serum creatinine of > 2.0 mg/dl at baseline will be excluded (to be drawn within 29 days prior to registration) Patients on Revlimid (lenalidomide) Patients on investigational chemotherapy/agents
Patient description: A 20 yo female college student with no significant past medical history presents with a chief complaint of fatigue. She reports increased sleep and appetite over the past few months as well as difficulty concentrating on her schoolwork. She no longer enjoys spending time with her friends and feels guilty for not spending more time with her family. Her physical exam and laboratory tests, including hemoglobin, hematocrit and thyroid stimulating hormone, are within normal limits.

Clinical trial eligibility criteria: eligible ages (years): 21.0-45.0,  Depression Anxiety Disorders No more than 28 weeks pregnant at the time of study entry History of depression or anxiety Current symptoms of distress Score of 9 or greater on the Edinburgh Postnatal Depression Scale (EPDS) English-speaking  Plans to move away from the area prior to giving birth Current use of steroids for medical conditions